V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

West Pharmaceutical Services Executive Compensation (FY25)

WST · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): May 5, 2026
341 figures on this page: 334 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
Median of the other named officers
$2,143,249
5 officers, excluding the chief executive
Latest say-on-pay support
=
May 4, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Eric Green: $8,394,201 → $7,190,876 (14.3% lower)
Say-on-pay support: 94.2% → 94.0% (0.2 points lower)

Frequently asked questions

Answers drawn from the data on this page.
What was West Pharmaceutical Services' say-on-pay result?
Shareholders supported the say-on-pay proposal with 94.0% of votes cast including abstentions in favor at the meeting held May 4, 2026 for fiscal 2025.
Which companies are in West Pharmaceutical Services' peer group?
The disclosed peer group includes Agilent Technologies, Inc., AptarGroup, Inc., Bio-Rad Laboratories, Inc., DENTSPLY SIRONA Inc. and Edwards Lifesciences Corporation, among others.
What is West Pharmaceutical Services' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 111:1, against median employee compensation of $64,635.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Eric Green
President and CEO, Chair of Board
◇—◇◇◇—◇◇
Bernard Birkett
Former SVP, Chief Financial Officer
◇—◇◇◇◇◇— not reconciled
Kimberly MacKay
Former SVP, General Counsel and Secretary
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Eric Green
President and CEO, Chair of Board
◇—◇◇◇◇◇◇
Bernard Birkett
Former SVP, Chief Financial Officer
◇—◇◇◇—◇◇
Annette Favorite
SVP, Chief Human Resources Officer
◇—◇◇◇◇◇◇
Kimberly MacKay
Former SVP, General Counsel and Secretary
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert McMahon
SVP, Chief Financial Officer
◇◇◇◇◇—◇◇
Eric Green
President and Chief Executive Officer, Chair of Board
◇—◇◇◇◇◇◇
Shane Campbell
SVP, Chief Proprietary Segment Officer
◇◇◇◇◇—◇◇
Bernard Birkett
Retired Senior Vice President, Chief Financial Officer
Departed during or after this year
◇—◇◇——◇◇
Annette Favorite
Senior Vice President, Chief Human Resources Officer
◇—◇◇◇◇◇◇
Kimberly MacKay
Former Senior Vice President, General Counsel and Secretary
Departed during or after this year
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Annette F. FavoritePSU◇◇◇◇◇—◇
Annette F. FavoriteOptions/SARs◇——◇—◇◇
Annette F. FavoriteRSU◇——◇——◇
Bernard J. BirkettRSU◇——◇——◇
Bernard J. BirkettOptions/SARs◇——◇—◇◇
Bernard J. BirkettPSU◇◇◇◇◇—◇
Eric M. GreenRSU◇——◇——◇
Eric M. GreenOptions/SARs◇——◇—◇◇
Eric M. GreenPSU◇◇◇◇◇—◇
Kimberly B. MacKayOptions/SARs◇——◇—◇◇
Kimberly B. MacKayRSU◇——◇——◇
Kimberly B. MacKayPSU◇◇◇◇◇—◇
Robert W. McMahonRSU◇——◇——◇
Robert W. McMahonOptions/SARs◇——◇—◇◇
Robert W. McMahonOptions/SARs◇——◇—◇◇
Robert W. McMahonPSU◇◇◇◇◇—◇
Robert W. McMahonPSU◇◇◇◇◇—◇
Robert W. McMahonRSU◇——◇——◇
Shane A. CampbellOptions/SARs◇——◇—◇◇
Shane A. CampbellRSU◇——◇——◇
Shane A. CampbellRSU◇——◇——◇
Shane A. CampbellPSU◇◇◇◇◇—◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Eric GreenOption◇—◇2/18/2035
Option◇—◇2/20/2034
PSU◇◇——
Option◇—◇2/21/2033
Option◇—◇2/22/2032
PSU◇◇——
PSU◇◇——
PSU◇◇——
Annette FavoriteOption◇—◇2/20/2034
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇2/22/2032
Option◇—◇2/21/2033
PSU◇◇——
Option◇—◇2/18/2035
Bernard BirkettOption◇—◇4/1/2026
PSU◇◇——
PSU◇◇——
Option◇—◇4/1/2026
Option◇—◇4/1/2026
Option◇—◇4/1/2026
Option◇—◇4/1/2026
PSU◇◇——
PSU◇◇——
Shane CampbellOption◇—◇5/12/2035
PSU◇◇——
PSU◇◇——
PSU◇◇——
Kimberly MacKayPSU◇◇——
Option◇—◇4/1/2026
PSU◇◇——
Option◇—◇4/1/2026
Option◇—◇4/1/2026
PSU◇◇——
PSU◇◇——
Option◇—◇4/1/2026
Robert McMahonOption◇—◇8/11/2035
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇8/11/2035
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Thomas W. Hofmann
◇◇———◇◇
Robert F. Friel
Lead independent director
◇◇————◇
Myla P. Lai-Goldman
◇◇———◇◇
Mark A. Buthman
◇◇———◇◇
Molly E. Joseph
◇◇———◇◇
Deborah L. V. Keller
◇◇————◇
Paolo Pucci
◇◇————◇
Janet B. Haugen
◇◇———◇◇
William F. Feehery
◇◇———◇◇
Douglas A. Michels
◇◇———◇◇
Stephen H. Lockhart
◇◇———◇◇
Eric M. Green served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Compensation committee chair◇
Equity is delivered as restricted stock units.
Stock ownership guideline: 5x annual retainer

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Agilent Technologies, Inc. A
  • AptarGroup, Inc. ATR
  • Bio-Rad Laboratories, Inc. BIO
  • DENTSPLY SIRONA Inc. XRAY
  • Edwards Lifesciences Corporation EW
  • Haemonetics Corporation HAE
  • Hologic, Inc. HOLX
  • IDEXX Laboratories, Inc. IDXX
  • Integer Holdings Corporation ITGR
  • Integra LifeSciences IART
  • ResMed Inc. RMD
  • Revvity, Inc. RVTY
  • STERIS plc STE
  • Teleflex Incorporated TFX
  • The Cooper Companies, Inc. COO

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 4, 2026=◇◇◇
2024May 6, 2025=◇◇◇
2023April 23, 2024=◇◇◇
2022April 25, 2023=◇◇◇
2021May 24, 2022=◇◇◇
2020May 4, 2021=◇◇◇
2019May 5, 2020=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when West Pharmaceutical Services files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact West Pharmaceutical Services disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where West Pharmaceutical Services sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether West Pharmaceutical Services' disclosed peer group is defensible, who names West Pharmaceutical Services back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
341 figures on this page: 334 cited to the filing that reported them, 7 calculated from figures it prints.
334 cited to the filing
7 calculated from the filing

Documents cited

  1. 0000105770-26-000056
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001104659-26-026778
    2025 Non-Employee Director Compensation · 2025 Summary Compensation · CEO Pay Ratio · HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM · and 1 more section
  3. 0000105770-25-000039
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001558370-25-003461
    Summary Compensation Table
  5. 0000105770-24-000035
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001558370-24-003056
    Summary Compensation Table
  7. 0000105770-23-000026
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0000105770-22-000026
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0000105770-21-000030
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0000105770-20-000025
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “West Pharmaceutical Services executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/WST (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about West Pharmaceutical Services and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers West Pharmaceutical Services discloses

The companies named in WST's own disclosed peer group.

Agilent Technologies, Inc.Bio-Rad Laboratories, Inc.DENTSPLY SIRONA Inc.Edwards Lifesciences CorporationHaemonetics CorporationHologic, Inc.Integer Holdings CorporationIntegra LifeSciencesResMed Inc.Revvity, Inc.STERIS plcTeleflex IncorporatedThe Cooper Companies, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy